The Fungal Meningitis drugs in development market research report provides comprehensive information on the therapeutics under development for Fungal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fungal Meningitis. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Fungal Meningitis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fungal Meningitis and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Fungal Meningitis by eight companies/universities/institutes. The top development phase for Fungal Meningitis is preclinical with three drugs in that stage. The Fungal Meningitis pipeline has five drugs in development by companies and three by universities/ institutes. Some of the companies in the Fungal Meningitis pipeline products market are: Mycovia Pharmaceuticals, Pfizer and Second Military Medical University.

The key targets in the Fungal Meningitis pipeline products market include GPI Anchored Wall Transfer Protein 1 (PfGWT1 or EC 2.3.), Thymidylate Synthase (TYMS or EC 2.1.1.45), and Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154).

The key mechanisms of action in the Fungal Meningitis pipeline product include Thymidylate Synthase (TYMS or EC 2.1.1.45) Inhibitor with two drugs in Phase I. The Fungal Meningitis pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Fungal Meningitis pipeline products market including Small Molecule, and Vaccine.

Fungal Meningitis overview

Fungal meningitis a rare, non-contagious, life-threatening fungal infection that causes swelling of the areas around the brain and spinal cord. It is caused due to breathing in fungal spores. The infection can spread from the lungs to the brain or spinal cord. Candida albicans and Cryptococcus neoformans are the most common fungi responsible for meningitis. Symptoms include fever, headache, stiff neck, light sensitivity, and confusion. It can be diagnosed by collecting samples of blood or cerebrospinal fluid and identifying fungus in it. Treatment includes high dose anti-fungal medications.

For a complete picture of Fungal Meningitis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.